Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + tuvonralimab + lenvatinib for second-line or later advanced renal cell carcinoma
ChiCTR2600124272Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and lenvatinib in clear cell renal cell carcinoma (ccRCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2600124272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124272.